Syndax Pharmaceuticals, Inc.

SNDXNASDAQ • USD
9.10 USD
↘ 0.04 (0.38%)🟢PRE MARKET (AS OF 07:01 AM EST)
🟢Market: OPEN

SNDX is currently priced at $9.10. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (1219.3%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 16, 2026.

Open?$9.19
High?$9.19
Low?$9.10
Prev. Close?$9.13
Volume?144
Avg. Volume?3.5M
VWAP?$9.10
Rel. Volume?0.00x
Bid / Ask
Bid?$7.80 × 100
Ask?$11.09 × 100
Spread?$3.29
Midpoint?$9.45
Valuation & Ratios
Market Cap?822.0M
Shares Out?90.0M
Float?84.2M
Float %?95.0%
P/E Ratio?N/A
P/B Ratio?-47.84
EPS?-$2.33
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Employees
298
Market Cap
850.8M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2016-03-03
Address
730 THIRD AVENUE
NEW YORK, NY 10017
Phone: 781-419-1400
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
0
Momentum?
62
Short Sent.?
40
Piotroski F-Score?4/9Mixed
Altman Z-Score?-2.24Distress
Confidence?58%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?22.47%Squeeze Risk
Short Interest?18.9M
Days to Cover?6.4
Free Float84.2M
Avg Daily Volume3.0M
Settlement Date2026-10-30
Financial Health
Current Ratio?4.69Strong
Quick Ratio?4.37Strong
Cash Ratio?1.12Strong
Debt/Equity?-14.25Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A▾
P/B?
S&P
97
-47.84CHEAP▾
P/S?
Peers
100
S&P
53
2.84CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.6CHEAP▾
EV/Sales?
Peers
100
S&P
58
3.21FAIR▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
1,219.3%STRONG▾
ROA?
S&P
3
-30.2%WEAK▾
Cash Flow & Enterprise
FCF?$-177546000
Enterprise Value?$930.8M
Fundamentals ratios updated end of day